The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics

Toxicology Letters

Volumn 186, Issue 1, 2009, Pages 45-51

  Ferrer Alcón, Marcel ^a   Arteta, David ^a   Guerrero, M José ^b   Fernandez Orth, Dietmar ^a   Simón, Laureano ^b   Martinez, Antonio ^a  

^a Progenika Biopharma SA   (Spain)

^b Proteomika SL Zamudio Technology Park   (Spain)

Author keywords

Functional genomics; Gene expression; Microarrays; Protein expression; Therapeutic targets

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOINFORMATICS; DNA MICROARRAY; DRUG TARGETING; FUNCTIONAL GENOMICS; HAPLOTYPE MAP; HUMAN; HUMAN GENOME; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

BIOLOGICAL MARKERS; DRUG DESIGN; DRUG DISCOVERY; DRUG THERAPY; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS;

EID: 61349108074     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.10.014     Document Type: Article

References (97)

1. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 53 (2007) 852-858
2. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson Jr. J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., and Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
3. Alon U., Barkai N., Notterman D.A., Gish K., Ybarra S., Mack D., and Levine A.J. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6745-6750
4. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., and Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2610-2615
5. Balganesh T.S., and Furr B.J. Molecular approaches to target discovery: evaluating targets for anti-tuberculosis drug discovery programmes. Infect. Disord. Drug Targets 7 (2007) 120-126
6. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., and Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6 (2006) 3414-3425
7. Beaudet A.L., and Belmont J.W. Array-based DNA diagnostics: let the revolution begin. Annu. Rev. Med. 59 (2008) 113-129
8. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., and Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003) 711-723
9. Bertucci F., and Goncalves A. Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncol. 4 (2008) 271-287
10. Bibikova M., Chudin E., Arsanjani A., Zhou L., Garcia E.W., Modder J., Kostelec M., Barker D., Downs T., Fan J.B., and Wang-Rodriguez J. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 89 (2007) 666-672
11. Blagosklonny M.V. A new science-business paradigm in anticancer drug development. Trends Biotechnol. 21 (2003) 103-106
12. Brown D. Unfinished business: target-based drug discovery. Drug Discov. Today 12 (2007) 1007-1012
13. Cazares L.H., Diaz J.I., Drake R.R., and Semmes O.J. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol. Biol. 428 (2008) 125-140
14. Chakravarti B., Oseguera M., Dalal N., Fathy P., Mallik B., Raval A., and Chakravarti D.N. Proteomic profiling of aging in the mouse heart: altered expression of mitochondrial proteins. Arch. Biochem. Biophys. 474 (2008) 22-31
15. Chaurand P., Sanders M.E., Jensen R.A., and Caprioli R.M. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am. J. Pathol. 165 (2004) 1057-1068
16. Chee M., Yang R., Hubbell E., Berno A., Huang X.C., Stern D., Winkler J., Lockhart D.J., Morris M.S., and Fodor S.P. Accessing genetic information with high-density DNA arrays. Science 274 (1996) 610-614
17. Chumbalkar V., Sawaya R., and Bogler O. Proteomics: the new frontier also for brain tumor research. Curr. Probl. Cancer 32 (2008) 143-154
18. Chung C.H., Levy S., Chaurand P., and Carbone D.P. Genomics and proteomics: emerging technologies in clinical cancer research. Crit. Rev. Oncol. Hematol. 61 (2007) 1-25
19. Clarke R., Ressom H.W., Wang A., Xuan J., Liu M.C., Gehan E.A., and Wang Y. The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat. Rev. Cancer 8 (2008) 37-49
20. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., Fisher R.I., Braziel R.M., Rimsza L.M., Grogan T.M., Miller T.P., LeBlanc M., Greiner T.C., Weisenburger D.D., Lynch J.C., Vose J., Armitage J.O., Smeland E.B., Kvaloy S., Holte H., Delabie J., Connors J.M., Lansdorp P.M., Ouyang Q., Lister T.A., Davies A.J., Norton A.J., Muller-Hermelink H.K., Ott G., Campo E., Montserrat E., Wilson W.H., Jaffe E.S., Simon R., Yang L., Powell J., Zhao H., Goldschmidt N., Chiorazzi M., and Staudt L.M. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351 (2004) 2159-2169
21. De Lellis L., Curia M.C., Aceto G.M., Toracchio S., Colucci G., Russo A., Mariani-Costantini R., and Cama A. Analysis of extended genomic rearrangements in oncological research. Ann. Oncol. 18 Suppl. 6 (2007) vi173-vi178
22. Desai A.A., Hysi P., and Garcia J.G. Integrating genomic and clinical medicine: searching for susceptibility genes in complex lung diseases. Transl. Res. 151 (2008) 181-193
23. Dyrskjot L., Kruhoffer M., Thykjaer T., Marcussen N., Jensen J.L., Moller K., and Orntoft T.F. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64 (2004) 4040-4048
24. Egner U., Kratzschmar J., Kreft B., Pohlenz H.D., and Schneider M. The target discovery process. Chembiochem 6 (2005) 468-479
25. Eszlinger M., Krohn K., Kukulska A., Jarzab B., and Paschke R. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr. Rev. 28 (2007) 322-338
26. Fels L.M., Buschmann T., Meuer J., Reymond M.A., Lamer S., Rocken C., and Ebert M.P. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer. Dig. Dis. 21 (2003) 292-298
27. Gagnon A., Shi Q., and Ye B. Surface-enhanced laser desorption/ionization mass spectrometry for protein and peptide profiling of body fluids. Methods Mol. Biol. 441 (2008) 41-56
28. Galasinski S.C., Resing K.A., and Ahn N.G. Protein mass analysis of histones. Methods 31 (2003) 3-11
29. Gupta P., and Lee K.H. Genomics and proteomics in process development: opportunities and challenges. Trends Biotechnol. 25 (2007) 324-330
30. Hiltunen M.O., Tuomisto T.T., Niemi M., Brasen J.H., Rissanen T.T., Toronen P., Vajanto I., and Yla-Herttuala S. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis 165 (2002) 23-32
31. Ho L., Guo Y., Spielman L., Petrescu O., Haroutunian V., Purohit D., Czernik A., Yemul S., Aisen P.S., Mohs R., and Pasinetti G.M. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci. Lett. 298 (2001) 191-194
32. Hocquette J.F. Where are we in genomics?. J. Physiol. Pharmacol. 56 Suppl. 3 (2005) 37-70
33. Horrobin D.F. Realism in drug discovery-could Cassandra be right?. Nat. Biotechnol. 19 (2001) 1099-1100
34. Huang J.T., Leweke F.M., Oxley D., Wang L., Harris N., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Reed B., and Bahn S. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 3 (2006) e428
35. Huang J.T., Leweke F.M., Tsang T.M., Koethe D., Kranaster L., Gerth C.W., Gross S., Schreiber D., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Holmes E., and Bahn S. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE. 2 (2007) e756
36. Huang J.T., Wang L., Prabakaran S., Wengenroth M., Lockstone H.E., Koethe D., Gerth C.W., Gross S., Schreiber D., Lilley K., Wayland M., Oxley D., Leweke F.M., and Bahn S. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatry 13 (2008) 1118-1128
37. Issaq H., and Veenstra T. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): advances and perspectives. Biotechniques 44 (2008) 697-698 700
38. Kaletta T., and Hengartner M.O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov. 5 (2006) 387-398
39. Kiehntopf M., Siegmund R., and Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin. Chem. Lab Med. 45 (2007) 1435-1449
40. Kim Y.S., Maruvada P., and Milner J.A. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol. 4 (2008) 93-102
41. Klijn C., Holstege H., de Ridder J., Liu X., Reinders M., Jonkers J., and Wessels L. Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res. 36 (2008) e13
42. Kocher T., and Superti-Furga G. Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat. Methods 4 (2007) 807-815
43. Konradi C. Gene expression microarray studies in polygenic psychiatric disorders: applications and data analysis. Brain Res. Brain Res. Rev. 50 (2005) 142-155
44. LaFerla F.M. An array of genes implicated in Alzheimer's disease. Neurobiol. Aging 27 (2006) 1078-1080
45. Lindsay M.A. Target discovery. Nat. Rev. Drug Discov. 2 (2003) 831-838
46. Lipshutz R.J., Fodor S.P., Gingeras T.R., and Lockhart D.J. High density synthetic oligonucleotide arrays. Nat. Genet. 21 (1999) 20-24
47. List E.O., Berryman D.E., Bower B., Sackmann-Sala L., Gosney E., Ding J., Okada S., and Kopchick J.J. The use of proteomics to study infectious diseases. Infect. Disord. Drug Targets 8 (2008) 31-45
48. Lockhart D.J., Dong H., Byrne M.C., Follettie M.T., Gallo M.V., Chee M.S., Mittmann M., Wang C., Kobayashi M., Horton H., and Brown E.L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14 (1996) 1675-1680
49. Lockhart D.J., and Winzeler E.A. Genomics, gene expression and DNA arrays. Nature 405 (2000) 827-836
50. Lockstone H.E., Harris L.W., Swatton J.E., Wayland M.T., Holland A.J., and Bahn S. Gene expression profiling in the adult Down syndrome brain. Genomics 90 (2007) 647-660
51. Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin III E.F., Liotta L.A., Patton W.F., Whiteley G.R., Rosenblatt K., Gurnani P., Nandi A., Neill S., Cullen S., O'Gorman M., Sarracino D., Lynch C., Johnson A., Mckenzie W., and Fishman D. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 53 (2007) 1067-1074
52. Loring J.F., Wen X., Lee J.M., Seilhamer J., and Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 20 (2001) 683-695
53. Luo J., Duggan D.J., Chen Y., Sauvageot J., Ewing C.M., Bittner M.L., Trent J.M., and Isaacs W.B. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61 (2001) 4683-4688
54. MacBeath G., and Schreiber S.L. Printing proteins as microarrays for high-throughput function determination. Science 289 (2000) 1760-1763
55. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M., Atkinson E.N., Smith D.I., Hartmann L., Fishman D., Berchuck A., Whitaker R., Gershenson D.M., Mills G.B., Bast Jr. R.C., and Lu K.H. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 11 (2005) 6116-6126
56. Martin-Ventura J.L., Blanco-Colio L.M., Tunon J., Gomez-Guerrero C., Michel J.B., Meilhac O., and Egido J. Proteomics in atherothrombosis: a future perspective. Expert Rev. Proteomics 4 (2007) 249-260
57. Mathivanan S., and Pandey A. Human proteinpedia as a resource for clinical proteomics. Mol. Cell Proteomics 7 (2008) 2038-2047
58. Micallef J., Gajadhar A., Wiley J., DeSouza L.V., Michael Siu K.W., and Guha A. Proteomics: present and future implications in neuro-oncology. Neurosurgery 62 (2008) 539-555
59. Miller D.T., Ridker P.M., Libby P., and Kwiatkowski D.J. Atherosclerosis: the path from genomics to therapeutics. J. Am. Coll. Cardiol. 49 (2007) 1589-1599
60. Miyazaki K., Yamaguchi M., Suguro M., Choi W., Ji Y., Xiao L., Zhang W., Ogawa S., Katayama N., Shiku H., and Kobayashi T. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression. Br. J. Haematol. 142 (2008) 562-570
61. Mu J., Yang Z.S., and Xie P. Proteomic analysis of a rat model of depression. Expert Rev. Proteomics 5 (2008) 315-320
62. Nakazawa T., Yamaguchi M., Okamura T.A., Ando E., Nishimura O., and Tsunasawa S. Terminal proteomics: N- and C-terminal analyses for high-fidelity identification of proteins using MS. Proteomics 8 (2008) 673-685
63. Namjou B., Kilpatrick J., and Harley J.B. Genetics of clinical expression in SLE. Autoimmunity 40 (2007) 602-612
64. Natt F. siRNAs in drug discovery: target validation and beyond. Curr. Opin. Mol. Ther. 9 (2007) 242-247
65. Negrisolo E., Bargelloni L., Patarnello T., Ozouf-Costaz C., Pisano E., di Prisco G., and Verde C. Comparative and evolutionary genomics of globin genes in fish. Methods Enzymol. 436 (2008) 511-538
66. Ornstein D.K., and Tyson D.R. Proteomics for the identification of new prostate cancer biomarkers. Urol. Oncol. 24 (2006) 231-236
67. Papassotiropoulos A., Fountoulakis M., Dunckley T., Stephan D.A., and Reiman E.M. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J. Clin. Psychiatry 67 (2006) 652-670
68. Pratt J.A., Winchester C., Egerton A., Cochran S.M., and Morris B.J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br. J. Pharmacol. 153 Suppl. 1 (2008) S465-S470
69. Pujana M.A., Han J.D., Starita L.M., Stevens K.N., Tewari M., Ahn J.S., Rennert G., Moreno V., Kirchhoff T., Gold B., Assmann V., Elshamy W.M., Rual J.F., Levine D., Rozek L.S., Gelman R.S., Gunsalus K.C., Greenberg R.A., Sobhian B., Bertin N., Venkatesan K., Ayivi-Guedehoussou N., Sole X., Hernandez P., Lazaro C., Nathanson K.L., Weber B.L., Cusick M.E., Hill D.E., Offit K., Livingston D.M., Gruber S.B., Parvin J.D., and Vidal M. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 39 (2007) 1338-1349
70. Pusch W., and Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr. Pharm. Des. 11 (2005) 2577-2591
71. Renier C., Faraco J.H., Bourgin P., Motley T., Bonaventure P., Rosa F., and Mignot E. Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Pharmacogenet. Genomics 17 (2007) 237-253
72. Rickardson L., Fryknas M., Dhar S., Lovborg H., Gullbo J., Rydaker M., Nygren P., Gustafsson M.G., Larsson R., and Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer. 93 (2005) 483-492
73. Rogawski M.A. Brivaracetam: a rational drug discovery success story. Br. J. Pharmacol. 154 (2008) 1555-1557
74. Schimmer A.D., Thomas M.P., Hurren R., Gronda M., Pellecchia M., Pond G.R., Konopleva M., Gurfinkel D., Mawji I.A., Brown E., and Reed J.C. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res. 66 (2006) 2367-2375
75. Schneider M. A rational approach to maximize success rate in target discovery. Arch. Pharm. (Weinheim) 337 (2004) 625-633
76. Schwarz E., and Bahn S. Biomarker discovery in psychiatric disorders. Electrophoresis 29 (2008) 2884-2890
77. Schwarz E., and Bahn S. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br. J. Pharmacol. 153 Suppl. 1 (2008) S133-S136
78. Sleno L., and Emili A. Proteomic methods for drug target discovery. Curr. Opin. Chem. Biol. 12 (2008) 46-54
79. Sripichai O., and Fucharoen S. Genetic polymorphisms and implications for human diseases. J. Med. Assoc. Thai. 90 (2007) 394-398
80. Su X.D., Liang Y., Li L., Nan J., Brostromer E., Liu P., Dong Y., and Xian D. A large-scale, high-efficiency and low-cost platform for structural genomics studies. Acta Crystallogr. D Biol. Crystallogr. 62 (2006) 843-851
81. Tebbutt S.J., James A., and Pare P.D. Single-nucleotide polymorphisms and lung disease: clinical implications. Chest 131 (2007) 1216-1223
82. Tong Y.Q., Zhang Z.J., Liu B., Huang J., Liu H., Liu Y., Guo F.J., Zhou G.H., Xie P.L., Li Y.H., Zuo C.H., Hu J.Y., and Li G.C. Autoantibodies as potential biomarkers for nasopharyngeal carcinoma. Proteomics 8 (2008) 3185-3193
83. Tuomisto T.T., Korkeela A., Rutanen J., Viita H., Brasen J.H., Riekkinen M.S., Rissanen T.T., Karkola K., Kiraly Z., Kolble K., and Yla-Herttuala S. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2235-2240
84. Uttamchandani M., Li J., Sun H., and Yao S.Q. Activity-based protein profiling: new developments and directions in functional proteomics. Chembiochem 9 (2008) 667-675
85. Uttamchandani M., Wang J., and Yao S.Q. Protein and small molecule microarrays: powerful tools for high-throughput proteomics. Mol. Biosyst. 2 (2006) 58-68
86. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B., and Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1617-1628
87. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., and Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
88. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., Mehra R., Montie J.E., Pienta K.J., Sanda M.G., Kantoff P.W., Rubin M.A., Wei J.T., Ghosh D., and Chinnaiyan A.M. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353 (2005) 1224-1235
89. Wang Y., Klijn J., Zhang Y., Atkins D., and Foekens J. Gene expression profiles and prognostic markers for primary breast cancer. Methods Mol. Biol. 377 (2007) 131-138
90. Ward M. Biomarkers for Alzheimer's disease. Expert Rev. Mol. Diagn. 7 (2007) 635-646
91. Weintraub L.A., and Sarwal M.M. Microarrays: a monitoring tool for transplant patients?. Transpl. Int. 19 (2006) 775-788
92. Willis R.C. The proteomics of aging. J. Proteome Res. 6 (2007) 3367
93. Wu X.J., Stahl T., Hu Y., Kassie F., and Mersch-Sundermann V. The production of reactive oxygen species and the mitochondrial membrane potential are modulated during onion oil-induced cell cycle arrest and apoptosis in A549 cells. J. Nutr. 136 (2006) 608-613
94. Yanagisawa K., Shyr Y., Xu B.J., Massion P.P., Larsen P.H., White B.C., Roberts J.R., Edgerton M., Gonzalez A., Nadaf S., Moore J.H., Caprioli R.M., and Carbone D.P. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362 (2003) 433-439
95. Yang S., Liu T., Li S., Zhang X., Ding Q., Que H., Yan X., Wei K., and Liu S. Comparative proteomic analysis of brains of naturally aging mice. Neuroscience 154 (2008) 1107-1120
96. Yokoyama K., Ishikawa N., Igarashi S., Kawano N., Hattori K., Miyazaki T., Ogino S.I., Matsumoto Y., Takeuchi M., and Ohta M. Discovery of potent CCR4 antagonists: synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. Bioorg. Med. Chem. (2008)
97. Zeidan B.A., and Townsend P.A. SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res. 10 (2008) 107